Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects

Microvascular Research

Volumn 80, Issue 1, 2010, Pages 110-115

  Derosa, Giuseppe ^a   Ferrari, Ilaria ^a   D'Angelo, Angela ^a   Salvadeo, Sibilla A T ^a   Fogari, Elena ^a   Gravina, Alessia ^a   Mereu, Roberto ^a   Palumbo, Ilaria ^a   Maffioli, Pamela ^a   Randazzo, Sabrina ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cardiovascular risk; Endothelial dysfunction; Metalloproteinases; Post prandial hyperlipidemia

Indexed keywords

ADIPONECTIN; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; NITRITE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FAT INTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERLIPIDEMIA; MALE; NORMAL HUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY FATS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NITRATES; NITRITES; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 77953536451     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2010.03.012     Document Type: Article

References (39)

1. Alipour A., et al. Postprandial inflammation and endothelial dysfuction. Biochem. Soc. Trans. 2007, 35(3):466-469.
2. Cicero A.F., et al. Vascular remodelling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium 2007, 14(4-5):193-198.
3. De Bruin T.W., et al. Postprandial decrease in HDL cholesterol and HDL apo A-I in normal subjects in relation to triglyceride metabolism. Am. J. Physiol. 1991, 260(3 Pt 1):E492-E498.
4. Derosa G., et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006, 13(3):227-231.
5. Derosa G., et al. Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium 2007, 14(1):45-51.
6. Derosa G., et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diab. Metab. 2007, 33(2):129-134.
7. El Messal M., et al. Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia. Clin. Chim. Acta 2006, 366(1-2):185-189.
8. A desktop guide to type 2 diabetes mellitus. Diabet. Med. 1999, 16:716-730. European Diabetes Policy Group.
9. Friedewald W.T., et al. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
10. Fujimoto N., et al. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin. Chim. Acta 1993, 221(1-2):91-103.
11. Fujimoto N., et al. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clin. Chim. Acta 1994, 231(1):79-88.
12. Green L.C., et al. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal. Biochem. 1982, 126:131-138.
13. Halkes C.J., et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler. Thromb. Vasc. Biol. 2001, 21(9):1526-1530.
14. Hartung D., et al. Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions. Eur. J. Nucl. Med. Mol. Imaging 2007, 34(1):S1-S8.
15. Havel R.J., et al. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 1955, 34:1345-1353.
16. Hobbs R., Hoes A. Effective management of dyslipidaemia among patients with cardiovascular risk: updated recommendations on identification and follow-up. Eur. J. Gen. Pract. 2005, 11(2):68-75.
17. Ikeda U., Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin. Cardiol. 2003, 26(2):55-59.
18. Jastrzebska M., et al. Increased levels of factor VII, fibrinogen and activity of plasminogen activator inhibitor during postprandial triglyceridemia in patients with ischemic heart disease confirmed by angiography. Nutr. Metab. Cardiovasc. Dis. 1999, 9(1):33-40.
19. Karpe F., et al. Lipoprotein lipase in plasma after an oral fat load: relation to free fatty acids. J. Lipid Res. 1992, 33(7):975-984.
20. Karpe F., et al. HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age. Arterioscler. Thromb. 1993, 13(1):11-22.
21. Karpe F., et al. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994, 106(1):83-97.
22. Kay R.M., et al. Acute effects of the pattern of fat ingestion on plasma high density lipoprotein components in man. Atherosclerosis 1980, 36(4):567-573.
23. Klose S., Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J. Clin. Chem. Clin. Biochem. 1978, 15:121-130.
24. Lundberg J.O., Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler. Thromb. Vasc. Biol. 2005, 25(5):915-922.
25. Maggi F.M., et al. Lipoprotein remnants and endothelial dysfunction in the postprandial phase. J. Clin. Endocrinol. Metab. 2004, 89(6):2946-2950.
26. Matthews J.N.S., et al. Analysis of serial measurements in medical research. B.M.J. 1990, 300:230-235.
27. Norata G.D., et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007, 193(2):321-327.
28. Nordestgaard B.G., et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298(3):299-308.
29. Parks E.J. Recent findings in the study of postprandial lipemia. Curr. Atheroscler. Rep. 2001, 3(6):462-470.
30. Peake P.W., et al. The postprandial response of adiponectin to a high-fat meal in normal and insulin-resistant subjects. Int. J. Obes. Relat. Metab. Disord. 2003, 27(6):657-662.
31. Poppitt S.D., et al. Postprandial response of adiponectin, interleukin-6, tumor necrosis factor-alpha, and C-reactive protein to a high-fat dietary load. Nutrition 2008, 24(4):322-329.
32. Rubin D., et al. Postprandial plasma adiponectin decreases after glucose and high fat meal and is independently associated with postprandial triacylglycerols but not with - 11388 promoter polymorphism. Br. J. Nutr. 2008, 99(1):76-82.
33. Sierevogel M.J., et al. Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr. Pharm. Des. 2003, 9(13):1033-1040.
34. Silveira A., et al. Activation of coagulation factor VII during alimentary lipemia. Arterioscler. Thromb. 1994, 14(1):60-69.
35. Spallarossa P., et al. Postprandial serum induces apoptosis in endothelial cells: Role of polymorphonuclear-derived myeloperoxidase and metalloproteinase-9 activity. Atherosclerosis 2008, 198(2):458-467.
36. Tsai W.C., et al. Effects of oxidative stress on endothelial function after a high-fat meal. Clin. Sci. 2004, 106(3):315-319.
37. Wahlefeld A.W. Triglycerides determination after enzymatic hydrolysis. Methods of Enzymatic Analysis 1974, 18-31. Academic Press, Inc, New York. 2nd English Ed. H.U. Bermeyer (Ed.).
38. Winer B.J. Statistical Principles in Experimental Design 1971, McGraw-Hill, New York. 2nd Ed.
39. Yamauchi T., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7:941-946.